Type 2 Biomarkers Define a Prevalent Phenotype in Moderate-to-Severe, Uncontrolled Asthma Patients: A Pooled Analysis from Lebrikizumab All-Comers Phase 2 Trials

Conclusions In a pooled analysis of three trials designed to evaluate the effects of lebrikizumab treatment in moderate-to-severe uncontrolled asthma, 68% of patients had evidence of Type 2 inflammation using the specified cut-off values for periostin, blood eosinophils and FeNO.

Saved in:

Bibliographic Details
Published in:	Journal of allergy and clinical immunology Vol. 137; no. 2; p. AB108
Main Authors:	Korenblat, Phillip E., MD, FAAAAI, Hanania, Nicola A., MD, Corren, Jonathan, MD, Olssen, Julie K., MD, MS, Kamath, Nikhil, MD, Gray, Sarah, PhD, Martin, Nicolas, Holweg, Cecile T.J., PhD, Matthews, John G., MB, BS, MRSCP, PhD, Limb, Susan L., MD, Korom, Stephan
Format:	Journal Article
Language:	English
Published:	St. Louis Elsevier Inc 01-02-2016 Elsevier Limited
Subjects:	Allergy and Immunology Asthma Biomarkers Genotype & phenotype Health care industry
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Conclusions In a pooled analysis of three trials designed to evaluate the effects of lebrikizumab treatment in moderate-to-severe uncontrolled asthma, 68% of patients had evidence of Type 2 inflammation using the specified cut-off values for periostin, blood eosinophils and FeNO.
ISSN:	0091-6749 1097-6825
DOI:	10.1016/j.jaci.2015.12.478